Pressure Ulcer Clinical Trial
Official title:
A Single Site Randomized, Clinical Trial Comparing the Concomitant Use of MicroMatrix® With Cytal™ Wound Matrix 2-Layer to Standard of Care in Patients With Stage 3 or 4 Pressure Injuries
Verified date | March 2021 |
Source | Integra LifeSciences Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 & 4 pressure ulcers using ACell products.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 23, 2019 |
Est. primary completion date | September 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated informed consent form by subject or legally authorized representative. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female patients that are = 21 years of age. 4. Body Mass Index (BMI) <45. 5. At least one Stage 3 or 4 pressure injury (NPUAP Staging Guidelines) present at the Screening and/or Treatment Visit located in any of the following regions: 1. Occipital 2. Back 3. Flank 4. Upper Extremity i. Arm ii. Elbow iii. Wrist iv. Hand e. Sacral f. Hip g. Gluteal h. Ischial i. Lower Extremity i. Leg ii. Knee iii. Ankle iv. Heel v. Foot 6. Surface dimensions of pressure injury must be between 9 to 64 cm2 inclusive (as measured prior to treatment using a cm-scale ruler). The longest dimension must not exceed 10 cm; depth must not exceed 5 cm. 7. Wound must be >5 cm from the anus if colostomy not performed. 8. For lower extremity ulcers: Adequate arterial blood flow and perfusion near the site of the injury (the foot is warm to the touch and has palpable pulses), per Investigator judgement. 9. Confirmed pressure injury versus moisture-associated skin damage or friction injury. 10. Ability to maintain an intact occlusive dressing for 4-7 days with reinforcement without contamination of urine or stool. 11. Confirmed fecal (Colostomy) and/or urine incontinence (Foley) maintenance/management, if necessary. 12. Consent to off-loading (turns) from pressure sites a minimum of every 2 hours (if possible). 13. Consent to sharp debridement of necrotic tissue in the wound bed unless the wound has already undergone debridement within 5 days prior to the Treatment Visit. 14. For females of reproductive potential (defined as females = 55 years of age): Negative pregnancy test required prior to surgical debridement per hospital procedures. Exclusion Criteria: 1. Surgical treatment of pressure injury 30 days prior to the Treatment Visit and/or pressure injury in previously irradiated areas. 2. Inability to manage fecal and/or urine incontinence or patient refusal of its maintenance/management (as determined medically necessary). Patient may be rescreened and enrolled if urinary and/or fecal continence status or management change after failure to comply with requirement. 3. Allergy or hypersensitivity to materials in porcine-based study products (per subject report) or personal preference. 4. Currently treated for an active malignant disease. 5. Prior diagnosis of active malignant disease, and is less than 1 year disease-free. 6. History of malignancy within the wound. 7. Presence of any conditions that are contraindicated with NPWT. 8. Any condition associated with a wound healing abnormality (e.g.: connective tissue disorder or immune disorder). 9. Dermatologic comorbid disease (e.g., cutis laxa or collagen vascular disease). 10. Bleeding diathesis. 11. Patients with primary treatment ulcers from burns (from exposure to high heat) or venous leg ulcers. A patient may have concomitant non-pressure ulcers present in non-pressure ulcer treatment regions. 12. Received biological-based therapy in any pressure wound within 3 months of the Treatment Visit. 13. Severe or significant hypoalbuminemia (albumin <2.5 g/dL, and/or pre-albumin <5 mg/dL), or hypoproteinemia (protein <6 g/dL). 14. Moderate to severe anemia (Hgb <7 g/dL). 15. Severely uncontrolled diabetes mellitus (defined as HA1C >12%). 16. Subject report of concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study. 17. Subject report of previous participation in other interventional wound healing clinical investigation within 60 days prior to the Screening Visit. 18. The subject has any physical or psychiatric condition that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study |
Country | Name | City | State |
---|---|---|---|
United States | Saint Vincent's Medical Center | Jacksonville | Florida |
Lead Sponsor | Collaborator |
---|---|
Integra LifeSciences Corporation | St. Vincent's Hospital-Manhattan |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Complete Epithelialization | Number of participant wounds with complete epithelialization by 12 weeks. Complete wound closure (epithelialization) determination based on PI assessment. | 12 weeks | |
Secondary | Time to Complete Wound Epithelization | Time to complete wound epithelization between groups. | 12 weeks | |
Secondary | Rate of Wound Epithelization | Rate of wound epithelization between groups | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03351049 -
An RCT on Support Surfaces for Pressure Ulcer Prevention
|
N/A | |
Completed |
NCT05112068 -
Comparative Assessment of Effectiveness and Safety of Methods for Skin and Hair Care in Severe Intensive Care Unit Patients
|
||
Completed |
NCT05575869 -
Evaluation of the Impact of the PRONEtect Education Hub vs. Classic Lecture, on the Competencies of Nursing Students
|
N/A | |
Completed |
NCT03220451 -
Use of Adhesive Elastic Taping for the Therapy of Medium/Severe Pressure Ulcers in Spinal Cord Injured Patients
|
N/A | |
Terminated |
NCT05234632 -
Study to Evaluate the PICO 14 Negative Pressure Wound Therapy System in the Management of Acute and Chronic Wounds
|
N/A | |
Completed |
NCT04540822 -
Peripheral Catheter Pressure Ulcer Prevention in Pediatry : Use of Compresses Versus Standard Care
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT02092870 -
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
|
Phase 2 | |
Completed |
NCT01438541 -
A Multi-centre Evaluation of the Performance of Window Dressings on Subjects With High Risk Pressure Ulceration
|
Phase 4 | |
Completed |
NCT00365430 -
SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes
|
N/A | |
Completed |
NCT04251897 -
Novel Support Surface to Alleviate Pressure Ulcer
|
N/A | |
Completed |
NCT03391310 -
Use of Honey for Pressure Ulcers in Critically Ill Children
|
N/A | |
Recruiting |
NCT04559165 -
Efficacy and Safety of Sericin and Chitosan Cream for Preventing and Limiting the Progressive of Pressure Sore
|
N/A | |
Completed |
NCT05646121 -
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
|
||
Not yet recruiting |
NCT06421454 -
Clinical Trial for the Evaluation of Melatonin in the Treatment of Pressure Ulcers
|
N/A | |
Terminated |
NCT05547191 -
Evaluate Efficacy and Safety of ChloraSolv When Treating Pressure Ulcers in Need of Debridement
|
N/A | |
Completed |
NCT05458050 -
An Investigation to Identify Subjects Admitted to Hospital With an Increased Risk of Developing Pressure Ulcers
|
N/A | |
Active, not recruiting |
NCT03048357 -
Effectiveness of Freedom Bed Compared to Manual Turning in Prevention of Pressure Injuries in Persons With Limited Mobility Due to Traumatic Brain Injury and/or Spinal Cord Injury.
|
N/A | |
Completed |
NCT06025370 -
Pressures During Prone Positions in Healthy Volunteers
|
N/A | |
Recruiting |
NCT05033470 -
A Multicentre Prospective Study Evaluating an Off-loading Mattress Overlay System in Healing of Stage 3 Pressure Ulcers
|
N/A |